Visible tissue responsiveness: Metabolic and fibroblast activity during utilization of a bioabsorbable matrix in abdominal wall reconstruction

Matthew I. Goldblatt, M.D., FACS Department of Surgery, Medical College of Wisconsin Milwaukee, Wisconsin



Background

This patient was undergoing treatment for simultaneous colon and rectal cancers and had a prior low anterior colon resection procedure with a diverting ileostomy. The patient developed a significant hernia at his former ostomy site, which necessitated a repair that included a Transverses Abdominas (TAR) muscle release.

Due to the comorbidities and risk factors present, the patient, family and surgeon decided to use GORE® ENFORM Preperitoneal Biomaterial, as part of the hernia repair to reinforce the soft tissue and support the TAR procedure. The Gore 3D PGA:TMC web scaffold has been studied in the clinical literature for over 20 years and has a targeted absorption period of six to seven months through hydrolysis that ensures no material is left behind, to avoid any potential risk of long-term complications that may be associated with mesh.

Device material

GORE® ENFORM Preperitoneal Biomaterial is a fully bioabsorbable matrix composed of the tissue-building web scaffold, Gore 3D PGA:TMC web scaffold that has been shown to promote rapid vascularity and ingrowth. Demonstrated vascularity was reported within seven days¹ and tissue ingrowth within one month.² The optimal porosity of the scaffold elicits a specific tissue response facilitating rapid cell migration and the formation of highly vascularized tissue.³,4 The 3D scaffold with highly interconnected pores provide tunnels for cellular migration, resulting in a structure that is similar to a collagen fiber network.

Metabolic activity observed

Patient was recovering well from the hernia repair and came in at three months for a CT scan as part of normal follow up. Additionally, the patient received a PET scan.

At three months, the patient's tissue response to the matrix material was clearly visible in the PET scan. From a metabolic standpoint: The GORE® ENFORM Preperitoneal Biomaterial was observed to be "glowing", as during the critical wound healing process, fibroblasts and collagen synthesis was occurring within the device. On subsequent follow up PET scans, the metabolic activity appeared to dissipate as the normal healing response progressed. Patient is currently doing well, with no complications or recurrences at over a year out from the index procedure.

- 1. Crawford N. Assessment of Vascularity via Micro CT in Various Patch Devices. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. [Final study report]. 2344TL.
- 2. Sanchez R. Tissue Characterization of GORE TRX, STRATTICE™ Reconstructive Tissue Matrix, XenMatrix™ Surgical Graft and Phasix ST™ Mesh in a Subcutaneous Rabbit Model at 30 and 90 days. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2018. [Study protocol]. 2466SC.
- Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants.II. Plasma-tissue exchange properties. *Journal of Biomedical Materials Research* 1998;40(4):586-597.
- Rosengren A, Bjursten LM. Pore size in implanted polypropylene filters is critical for tissue organization. Biomedical Materials Research. Part A. 2003;67(3):918-926.

Consult Instructions for Use eifu.goremedical.com

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. $R_{\rm Colp}$

Products listed may not be available in all markets.


GORE, ENFORM and designs are trademarks of W. L. Gore & Associates. © 2020 W. L. Gore & Associates, Inc. AZ2040-EN1 DECEMBER 2020

Patient initial pre-op CT scan showing significant hernia



Click here or on images for virtual case review »

Patient PET scan at three months illustrates cellular metabolic activity



Click here or on images for virtual case review »



W. L. GORE & ASSOCIATES, INC. Flagstaff, AZ 86004

+65 67332882 (Asia Pacific) 1 800 680 424 (Australia/New Zealand) 00800 6334 4673 (Europe) 800 437 8181 (United States) 928 779 2771 (United States)

goremedical.com